SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Catalytic Atroposelective Synthesis for Revealing Elusive Bioactive Conformations and Shapes

AtropShape aims to develop new catalytic methods for synthesizing diverse atropisomeric molecules to enhance drug discovery by exploring their unique pharmacological properties.

Subsidie
€ 1.499.041
2025

Projectdetails

Introduction

Atropisomeric molecules (atropisomers) are separable conformational isomers arising from restricted rotation around a single bond. Atropisomers have revolutionized the treatment of several deadly diseases. The principal goal of AtropShape is to create pharmaceutical leads with unusual conformations and shapes by developing catalytic stereoselective (atroposelective) synthesis methods toward difficult-to-access drug-like atropisomers.

Importance of Atropisomers

Because atropisomers are chiral, they give rise to two or more isomers that have different pharmacological properties. These attributes relate to a crucial, yet minimally investigated and poorly understood fundamental question of how conformational changes, from achiral and relatively planar to chiral and more tridimensional atropisomeric forms, impact a molecule’s ability to interact with biological receptors.

Method Development

To study such a range of atropisomers and related concepts, one must first create them. Therefore, I will introduce three new catalytic atroposelective methods:

  1. We will develop unprecedented atroposelective amide-bond formations and apply them to the synthesis of the first examples of peptidomimetics with an atropisomeric amide moiety.
  2. We will efficiently generate, by alkyne cyclization strategies, sphere-shaped atropisomers. This rarely investigated area of molecular shape is much sought-after in drug discovery.
  3. We will introduce the first instances of atroposelective decarboxylation of esters.

Expected Outcomes

The proposed methods will offer direct access to an assortment of bioactive atropisomers, which will be easily modifiable to generate, by diversity-oriented synthesis approaches, libraries of drug-like molecules that will be tested broadly in medicinal chemistry.

Conclusion

Collectively, the resulting knowledge will shed light on key differences between the pharmacological properties of achiral compounds and chiral atropisomeric molecules, constituting invaluable insight for drug discovery and development.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.041
Totale projectbegroting€ 1.499.041

Tijdlijn

Startdatum1-1-2025
Einddatum31-12-2029
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.penvoerder

Land(en)

Czechia

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Advanced Molecular ENantiodiscrimination

The AMEN project aims to develop scalable chiral microreactor technology for the selective production of pharmaceutical enantiomers, ensuring safety and efficacy in drug formulations.

ERC Proof of...€ 150.000
2024
Details

A Leap in Ligand Technology: The Development and Valorization of Novel Chiral Diphosphine Ligands

This project aims to develop a new class of efficient chiral phosphine ligands through a simplified catalytic synthesis, enhancing production and diversity for pharmaceutical applications.

ERC Proof of...€ 150.000
2025
Details

Early-Stage Organocatalysis

The project aims to develop next-generation organocatalysts for selective early-stage functionalization of hydrocarbons, enhancing efficiency in producing high-value chemicals.

ERC Advanced...€ 2.500.000
2022
Details

Catalytic Light-induced Deracemization

The CALIDE project aims to develop innovative photocatalytic methods for the efficient conversion of racemates into enantiomerically pure compounds using light, reducing waste in chiral synthesis.

ERC Advanced...€ 2.447.299
2025
Details

Energy Transfer Catalysis: A Highway to Molecular Complexity

HighEnT aims to innovate synthetic methodologies using visible light-mediated EnT catalysis to create complex organic molecules for pharmacological applications, enhancing chemical space and reaction design.

ERC Advanced...€ 2.499.250
2023
Details
ERC Proof of...

Advanced Molecular ENantiodiscrimination

The AMEN project aims to develop scalable chiral microreactor technology for the selective production of pharmaceutical enantiomers, ensuring safety and efficacy in drug formulations.

ERC Proof of Concept
€ 150.000
2024
Details
ERC Proof of...

A Leap in Ligand Technology: The Development and Valorization of Novel Chiral Diphosphine Ligands

This project aims to develop a new class of efficient chiral phosphine ligands through a simplified catalytic synthesis, enhancing production and diversity for pharmaceutical applications.

ERC Proof of Concept
€ 150.000
2025
Details
ERC Advanced...

Early-Stage Organocatalysis

The project aims to develop next-generation organocatalysts for selective early-stage functionalization of hydrocarbons, enhancing efficiency in producing high-value chemicals.

ERC Advanced Grant
€ 2.500.000
2022
Details
ERC Advanced...

Catalytic Light-induced Deracemization

The CALIDE project aims to develop innovative photocatalytic methods for the efficient conversion of racemates into enantiomerically pure compounds using light, reducing waste in chiral synthesis.

ERC Advanced Grant
€ 2.447.299
2025
Details
ERC Advanced...

Energy Transfer Catalysis: A Highway to Molecular Complexity

HighEnT aims to innovate synthetic methodologies using visible light-mediated EnT catalysis to create complex organic molecules for pharmacological applications, enhancing chemical space and reaction design.

ERC Advanced Grant
€ 2.499.250
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Cascades for Stereoselective Synthesis of Amino Acids

cassaFLOW aims to develop a 3-step biocatalytic synthesis of non-natural isoleucine, streamlining production for pharmaceuticals like Paxlovid and enhancing EU strategic autonomy.

EIC Transition€ 2.378.694
2024
Details
EIC Transition

Cascades for Stereoselective Synthesis of Amino Acids

cassaFLOW aims to develop a 3-step biocatalytic synthesis of non-natural isoleucine, streamlining production for pharmaceuticals like Paxlovid and enhancing EU strategic autonomy.

EIC Transition
€ 2.378.694
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.